Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(3.45)
# 1,001
Out of 5,124 analysts
52
Total ratings
36.96%
Success rate
10.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Overweight | n/a | $17.12 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $582.34 | - | 5 | Nov 5, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $18.16 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $69.55 | -6.54% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $8.18 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $38.21 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $3.01 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $20.36 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $0.78 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $6.98 | +43.27% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.18 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.87 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $29.81 | -19.49% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.23 | +13,831.89% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $1.55 | +803.23% | 1 | Mar 3, 2021 |
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $17.12
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $582.34
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $18.16
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $69.55
Upside: -6.54%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.18
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $38.21
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.01
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $20.36
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.78
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $6.98
Upside: +43.27%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.18
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $33.87
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $29.81
Upside: -19.49%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $3.23
Upside: +13,831.89%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $1.55
Upside: +803.23%